Mode
Text Size
Log in / Sign up

Individualized commercial formulation reduces diarrhea in adult ICU patients receiving tube-fed enteral nutrition.

Individualized commercial formulation reduces diarrhea in adult ICU patients receiving tube-fed ente…
Photo by Karim Ghantous / Unsplash
Key Takeaway
Note that individualized commercial formulation is associated with lower diarrhea rates in this retrospective cohort.

This retrospective cohort study evaluated 605 adult ICU patients receiving tube-fed enteral nutrition at Henan Provincial People's Hospital. The analysis compared an individualized commercial formulation (ICF) against standard commercial enteral nutrition (CEN). The primary outcome assessed was the incidence of diarrhea, while secondary outcomes included feeding interruption, gastric residual volume, constipation, hyperglycemia, and composite gastrointestinal complications.

Results indicated a lower incidence of diarrhea in the ICF group compared to the CEN group, with absolute rates of 13.6% versus 41.5%. The adjusted odds ratio was 0.27 (95% CI 0.11–0.68; p = 0.005). Additionally, fewer feeding interruptions occurred in the ICF group compared to the CEN group, with an incidence rate ratio of 0.29 (95% CI 0.18–0.45; p = 0.005). Data for other secondary outcomes were not reported in the provided text.

The study did not report specific adverse events, serious adverse events, discontinuations, or detailed tolerability metrics. As an observational study, causal inferences cannot be made. The findings suggest a potential benefit of ICF regarding gastrointestinal complications, but the retrospective nature and lack of randomization limit the certainty of these results. Clinicians should interpret these associations cautiously until supported by higher-quality evidence.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundCritically ill ICU patients often fail to achieve target caloric intake due to gastrointestinal intolerance. Although commercial enteral nutrition (CEN) formulas are the standard of care, emerging evidence suggests they may worsen intolerance in certain susceptible populations. Individualized commercial formulation (ICF) may help reduce related complications, but its safety and effectiveness compared to commercial formulas remain insufficiently validated.ObjectiveTo compare the associations of CEN, mixed feeding, and ICF with gastrointestinal tolerance and complication risk in ICU patients.MethodsIn this single-center retrospective cohort study, 605 adult ICU patients receiving tube-fed EN at Henan Provincial People’s Hospital between January 2023 and January 2025 were included. Patients were classified into Commercial (n = 477), Mixed (n = 84), and ICF (n = 44) groups according to EN source. The primary outcome was diarrhea. Secondary outcomes included feeding interruption, gastric residual volume, constipation, hyperglycemia, and composite gastrointestinal complications. Multivariable logistic regression was used to adjust for baseline and feeding-related factors. Missing data were handled by multiple imputation. Propensity score matching and APACHE II–stratified analyses were performed as sensitivity analyses.ResultsCompared with the Commercial group, the ICF group had a lower incidence of diarrhea (13.6% vs. 41.5%; aOR = 0.27, 95% CI 0.11–0.68; p = 0.005), fewer feeding interruptions (IRR = 0.29, 95% CI 0.18–0.45; p 
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.